Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Abstract Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic...

Full description

Bibliographic Details
Published in:	Rheumatology and Therapy
Main Authors:	Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-09-01
Subjects:	Disease activity Fatigue Guselkumab Joint disease Minimal clinically meaningful improvement Pain
Online Access:	https://doi.org/10.1007/s40744-024-00702-0

Similar Items

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
by: Laura C. Coates, et al.
Published: (2024-02-01)

Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
by: Jeffrey R. Curtis, et al.
Published: (2024-02-01)

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study
by: Christopher T. Ritchlin, et al.
Published: (2025-07-01)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
by: Philip J. Mease, et al.
Published: (2023-10-01)

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
by: Philip Mease, et al.
Published: (2024-09-01)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
by: Fabrizio Martora, MD, et al.
Published: (2023-11-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

The use of guselkumab in psoriatic arthritis: evidence from real clinical practice
by: N. V. Nekrasova, et al.
Published: (2021-12-01)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2023-08-01)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023-09-01)

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy
by: Andrew Blauvelt, et al.
Published: (2024-09-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study
by: Piero Ruscitti, et al.
Published: (2024-03-01)

Guselkumab for the treatment of pyoderma gangrenosum
by: Sera Sarsam, et al.
Published: (2025-03-01)

Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn&rsquo;s Disease
by: D'Amico F, et al.
Published: (2025-05-01)

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety
by: Astrid‐Helene Ravn Jørgensen, et al.
Published: (2020-12-01)

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks
by: Suzy van Sanden, et al.
Published: (2025-06-01)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
by: Georg Schett, et al.
Published: (2023-08-01)

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study
by: Philip J. Mease, et al.
Published: (2024-12-01)

Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis
by: Mirco Mastrangelo, et al.
Published: (2025-09-01)

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
by: Richard B. Warren, et al.
Published: (2024-03-01)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
by: Ricardo Ruiz-Villaverde, et al.
Published: (2022-09-01)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024-07-01)

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024-03-01)

Real-world experience of the efficacy and safety of guselkumab 100 mg in patients with palmoplantar pustulosis in Korea: A retrospective single-center study
by: Min Kyung Cho, MD, et al.
Published: (2025-02-01)

Successful treatment of pyoderma gangrenosum with guselkumab
by: Sofia Botvid, et al.
Published: (2025-03-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
by: Laure Gossec, et al.
Published: (2024-02-01)

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
by: Maryia Zhdanava, et al.
Published: (2024-12-01)

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial
by: William Tillett, et al.
Published: (2023-09-01)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-09-01)

Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II
by: Martora F, et al.
Published: (2025-09-01)

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome
by: Simge Ünal, et al.
Published: (2024-06-01)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022-08-01)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022-03-01)

Reactivation of latent hepatitis B infection during immunosuppressive therapy with guselkumab for plaque psoriasis: a case report
by: Elena Franchi, et al.
Published: (2023-12-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report
by: Nana Luo, et al.
Published: (2025-12-01)